All data are based on the daily closing price as of September 4, 2025
d

Daiichi Sankyo

4568.TSE
24.39 USD
0.49
+2.05%

Overview

Last close
24.39 usd
Market cap
45.43B usd
52 week high
42.03 usd
52 week low
21.45 usd
Target price
36.83 usd

Valuation

P/E
22.8844
Forward P/E
21.5983
Price/Sales
3.486
Price/Book Value
4.1925
Enterprise Value
41.34B usd
EV/Revenue
3.284
EV/EBITDA
14.2029

Key financials

Revenue TTM
12.98B usd
Gross Profit TTM
10.20B usd
EBITDA TTM
2.74B usd
Earnings per Share
1.06 usd
Dividend
0.4 usd
Total assets
23.18B usd
Net debt
-3.61B usd

About

Daiichi Sankyo Company, Limited manufactures and sells pharmaceutical products in Japan, North America, Europe, and internationally. The company offers Enhertu to treat patients with HER2 positive and low breast cancer, HER2 positive gastric or gastroesophageal junction adenocarcinoma, and HER2 positive solid tumors; Turalio, an oral small molecule that targets colony stimulating factor 1 receptor, KIT proto-oncogene receptor tyrosine kinase, and FMS-like tyrosine kinase 3 harboring an internal tandem duplication mutation; Vanflyta, a FLT3 inhibitor for the treatment of adult patients with acute myeloid leukemia; Injectafer, a ferric carboxymaltose injection to treat iron deficiency; and DATROWAY to treat adult patients with hormone receptor (HR) positive, and HER2 negative. It also provides Liziana and Savaysa, direct factor Xa inhibitors; Minnebro, Olmetec, Olmetec Plus, Rezaltas, Sevikar, and Sevikar HCT antihypertensive agents; Nilemdo, an oral treatment which lowers cholesterol; Nustendi, a fixed-dose combination tablet of bempedoic acid and ezetimibe to reduce cholesterol; and Efient, an anti-platelet agent. In addition, the company offers Canalia and Tenelia for the treatment of type 2 diabetes mellitus; Emgalty and Reyvow to treat migraine attacks; Pralia for the treatment of osteoporosis/inhibitor of the progression of bone erosion associated with rheumatoid arthritis; Ranmark to treat bone complications caused by bone metastasis from tumors; Tarlige for treating neuropathic pain; Venofer for the treatment of iron deficiency anemia; and Vimpat, an anti-seizure medication. Further, it provides vaccines for COVID-19 infection, influenza infection, adsorbed cell culture-derived influenza (H5N1), measles/rubella infection, and mumps. Daiichi Sankyo Company, Limited was founded in 1899 and is headquartered in Tokyo, Japan.
  • Symbol
    4568.TSE
  • Exchange
    TSE
  • Isin
    JP3475350009
  • Country
    Japan
  • Sector
    Healthcare
  • Industry
    Drug Manufacturers - General
  • CEO
    Mr. Sunao Manabe D.V.M., Ph.D.
  • Headquarter
    Tokyo
  • Web site
    https://www.daiichisankyo.com
Jakota Newsletter

Stay ahead in the JAKOTA stock markets with our roundup of vital insights

Icon scroll to top